Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    CRISPR
Show Display Options
Rank Status Study
1 Not yet recruiting A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
Condition: Human Papillomavirus-Related Malignant Neoplasm
Interventions: Biological: TALEN;   Biological: CRISPR/Cas9
2 Recruiting PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Interleukin-2;   Other: PD-1 Knockout T Cells
3 Not yet recruiting PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
Condition: Invasive Bladder Cancer Stage IV
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
4 Not yet recruiting PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
5 Not yet recruiting PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
6 Recruiting PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: Cyclophosphamide;   Other: PD-1 Knockout T Cells;   Drug: Interleukin-2
7 Not yet recruiting PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
Conditions: Stage IV Gastric Carcinoma;   Stage IV Nasopharyngeal Carcinoma;   T-Cell Lymphoma Stage IV;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Interleukin-2

Study has passed its completion date and status has not been verified in more than two years.